Just in:
Crypto Market Poised for Boom as Baby Boomers Embrace Bitcoin ETFs // Nano-Care Deutschland AG launches next generation of sustainable PFAS-free oleophobic coatings // Ministry of Agriculture Supports Taiwanese Tea’s Entry into Singapore Market to Boost Global Presence // Etihad Airways Announces Paris Service with A380 // UN Commends Vietnam’s Progress on Climate Goals // Forward Fashion’s Artelli Presents: Nobuyoshi Araki’s “Paradise” Starting from April 27th, at K11 MUSEA // GE Jun, Chairman and CEO of TOJOY, Delivers an Inspiring Speech: “Leaping Ahead Again” // Election Commission Of India Degrades Itself To Modi’s Own Commission // PolyU forms global partnership with ZEISS Vision Care to expand impact and accelerate market penetration of patented myopia control technology // Supreme Court dismisses pleas for 100% VVPAT verification // Oman Seeks Growth Through Strategic Economic Alliances // DIFC Courts Cement Role as Top English Dispute Resolution Choice // Why Lok Sabha Election For 20 Seats In Kerala Is Crucial For Future Of Left In Indian Politics? // World Football Federation Secures Sponsorship From Saudi Oil Giant // Galaxy Macau’s Sakura Cultural Festival Kicked off in Splendor // AVPN Charts Path Forward at 2024 Global Conference // Andertoons by Mark Anderson for Fri, 26 Apr 2024 // e& UAE Unveils Strategic Roadmap // Liverpool FC continues international growth with first official retail partnership in South Korea // CapBridge Shares Insights on the Recent Launch of Digital Asset ETFs in Hong Kong //

Cohen's SAC Capital in $135 million settlement with Elan investors

1480554738

By Jonathan Stempel and Nate Raymond
| NEW YORK

ADVERTISEMENT

NEW YORK Billionaire Steven A. Cohen’s former hedge fund SAC Capital Advisors LP will pay $135 million to settle a lawsuit by investors in the drugmaker Elan Corp, who said they lost money because of insider trading by one of his portfolio managers.

The preliminary class-action settlement with SAC, now known as Point72 Asset Management LP, was filed on Wednesday with the federal court in Manhattan, and requires approval by U.S. District Judge John Koeltl.

It resolves claims over an estimated $275 million of illegal trading gains in Elan and the drugmaker Wyeth by Mathew Martoma, who worked at SAC’s CR Intrinsic Investors unit, based on tips from a Michigan doctor about a 2008 Alzheimer’s drug trial.

“We are pleased to have resolved this matter and close the books on this chapter of SAC-era litigation,” Point72 spokesman Mark Herr said in a statement.

SAC pleaded guilty to fraud in 2013 and paid $1.8 billion in criminal and civil settlements with U.S. authorities. It settled with Wyeth shareholders for $10 million last December.

Martoma, meanwhile, is appealing his February 2014 insider trading conviction, while he serves a nine-year prison term.

Cohen, 60, was not criminally charged, but in January accepted a two-year ban on managing money for outside investors to end a U.S. Securities and Exchange Commission civil probe into his supervision of Martoma.

That ban ends on Jan. 1, 2018, and no fine was imposed. Point72 is based in Stamford, Connecticut.

SAC and Cohen did not admit wrongdoing in settling with the former Elan investors, including purchasers of its American depositary receipts and stock options.

Perrigo Co (PRGO.N) bought Elan in 2013, while Pfizer Inc (PFE.N) bought Wyeth in 2009.

Lawyers for the Elan investors plan to seek up to $35.1 million for legal fees and $2.8 million for costs, which would be drawn from the $135 million settlement, court papers show.

Cohen can donate leftover settlement funds to charities he chooses, with the consent of the Elan investors. He is worth $13 billion, Forbes magazine said.

The case is Kaplan et al v SAC Capital Advisors LP et al, U.S. District Court, Southern District of New York, No. 12-09350.

(Reporting by Jonathan Stempel and Nate Raymond in New York; editing by G Crosse, Grant McCool)

Reuters

ADVERTISEMENT

ADVERTISEMENT